Mechanism of Action
Cabergoline stimulates dopamine D2 receptors in the pituitary gland, suppressing prolactin secretion. Prolactin elevation from 19-nor compounds like Nandrolone and Trenbolone occurs through progestogenic activity at the pituitary. High prolactin causes gynecomastia through a different pathway than estrogen, sexual dysfunction, and galactorrhea. Cabergoline addresses this directly at the source.
Ester Profile
Oral ergot derivative. No ester. Extremely long half-life of 65-68 hours allows twice-weekly dosing. This extended half-life means it accumulates over the first few weeks of use before reaching steady state.
How It's Used in Fitness
Cabergoline is used specifically in protocols involving 19-nor compounds — Nandrolone and Trenbolone — to prevent or manage prolactin-related side effects. Prolactin gynecomastia does not respond to aromatase inhibitors or SERMs the way estrogen-mediated gynecomastia does. Cabergoline addresses the actual mechanism. It is also used to manage the sexual dysfunction that Nandrolone in particular causes, which is mediated partly through prolactin elevation.
Stacking Context
Cabergoline is added specifically when Nandrolone Decanoate, NPP, or Trenbolone are part of the stack. It is not needed alongside testosterone-only protocols or compounds that do not elevate prolactin. It pairs with Anastrozole or Exemestane in 19-nor stacks where both estrogen and prolactin management are required simultaneously. Running it without a prolactin-elevating compound in the stack is unnecessary.
Medical Use
- Hyperprolactinemia — primary medical use
- Prolactin-secreting pituitary tumors
- Parkinson's disease
- Prevention of postpartum lactation
- Approved and available by prescription in India
Side Effects
- Nausea — particularly at start of use
- Headache
- Postural hypotension — dizziness on standing
- Impulse control issues — rare at performance doses but documented at higher doses
- Cardiac valvulopathy risk with long-term high-dose use
- Fatigue
What Actually Goes Wrong
Cabergoline's dopaminergic activity produces compulsive behavior in a small subset of users — impulse control issues including compulsive gambling and hypersexuality have been documented in Parkinson's patients using higher doses. At performance doses these effects are rare but not absent. Cardiovascular valvulopathy has been associated with long-term high-dose use in Parkinson's patients. At the lower doses used in performance contexts for shorter durations, this risk is substantially lower but should be acknowledged. Nausea is common when starting, particularly at higher doses.
Detection Window
WADA bans dopamine agonists. Detection methodology available.
Cabergoline is one of those compounds that people either use appropriately because they are running 19-nor compounds and understand what prolactin control means, or they stumble into it because someone told them it would help with recovery time between sexual activity. The latter is a valid pharmacological effect but it is not a reason to add a potent dopamine agonist to your life. Use it for what it does well — prolactin management in 19-nor protocols — and only when those protocols are in use.